Revabiotech

RevaBiotech is a preclinical-stage biotechnology company focused on developing next-generation gene therapies for oncology and neurodegenerative diseases. The company utilizes its proprietary REVA (Rapid Evolution of Viral Assets) platform to engineer optimized Adeno-Associated Virus (AAV) vectors with enhanced tissue specificity and reduced immunogenicity. Their lead programs target complex conditions such as Alzheimer's disease and various solid tumors. By improving the delivery efficiency of genetic payloads, RevaBiotech aims to expand the therapeutic potential of gene medicine. The company's technology is designed to overcome the current limitations of viral vectors, such as off-target effects and pre-existing immunity. RevaBiotech is headquartered in Florida and leverages research from leading academic institutions to drive its innovation pipeline.